Biomerica Inc.
1533 Monrovia Avenue
Newport Beach
California
92663
United States
Tel: 714-645-2111-or-800-854-3002
Fax: 714-722-6674
Website: http://www.biomerica.com/
Email: bmra@biomerica.com
138 articles about Biomerica Inc.
-
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
2/21/2024
Biomerica, Inc. proudly announces the appointment of Gary Huff to its Strategic Advisory Board.
-
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
1/23/2024
Biomerica, Inc. today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica.
-
Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population
12/18/2023
Biomerica, Inc. today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test (K232892), a new product that is designed to detect the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population.
-
Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16
11/10/2023
Biomerica, Inc. today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City.
-
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
11/8/2023
Biomerica, Inc., a global provider of advanced medical products announced that several new Gastrointestinal groups have signed up and begun using the Company's revolutionary inFoods® IBS Product.
-
REPEAT - Biomerica Reports First Quarter 2024 Financial Results
10/13/2023
Biomerica, Inc., a global provider of advanced medical diagnostic and therapeutic products reported financial results for the first quarter of fiscal 2024 ended August 31, 2023.
-
Biomerica Reports First Quarter 2024 Financial Results
10/13/2023
Biomerica, Inc., a global provider of advanced medical diagnostic and therapeutic products reported financial results for the first quarter of fiscal 2024 ended August 31, 2023.
-
Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test
9/26/2023
Biomerica, Inc. announced that the Dubai government has officially approved insurance reimbursement for the EZ Detect colorectal disease at-home screening test, which is designed to detect an early warning sign of colorectal cancer and other colorectal diseases.
-
Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors
8/28/2023
Biomerica Inc., a global biomedical company leading the way in innovative gastroenterology solutions, announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors.
-
Biomerica Reports Fiscal 2023 Year End Results
8/25/2023
Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2023 financial results.
-
CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test
8/3/2023
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that CVS Pharmacy has begun in-store sales rollout of the Company’s EZ Detect™ colorectal disease screening test in over 7,000 stores nationwide throughout the CVS Pharmacy retail system.
-
Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology
6/21/2023
Biomerica Inc. announced that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a patent application that covers a development stage information technology (“IT”) system.
-
inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology
5/18/2023
Biomerica Inc., a global biomedical company leading the way in innovative gastroenterology solutions, announced a significant advance in the management of irritable bowel syndrome.
-
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
4/17/2023
Biomerica, Inc. is pleased to announce that inFoods® IBS, a revolutionary new approach to alleviate Irritable Bowel Syndrome symptoms, is now available at the flagship office of Gastro Health in Miami, with plans expand into the other Gastro Health offices in the future.
-
Biomerica Reports Q3 Fiscal 2023 Results
4/14/2023
Biomerica, Inc., a global provider of advanced medical diagnostic and therapeutic products, announced its fiscal third quarter and nine month results ended February 28, 2023.
-
Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock
3/7/2023
Biomerica, Inc. announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock.
-
Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock
3/3/2023
Biomerica, Inc. announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share.
-
Biomerica Announces Proposed Underwritten Public Offering of Common Stock - March 02, 2023
3/2/2023
Biomerica, Inc., a global provider of advanced medical products, announced that it has commenced an underwritten public offering of its common stock.
-
Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022
1/13/2023
Biomerica, Inc., a global provider of advanced medical products, reported its second quarter fiscal 2023 financial results for the period ended November 30, 2022.
-
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
1/10/2023
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board.